IOVA Stock Analysis: Iovance Biotherapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.768m USD | 12M Return: 155.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 54.8M
Qual. Beats: -1
Rev. Trend: 92.0%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Iovance Biotherapeutics (IOVA) is a commercial-stage biopharmaceutical company headquartered in San Carlos, California, that develops and commercializes autologous cell therapies using tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers, with a focus on metastatic melanoma. Autologous TIL therapy is a form of personalized immunotherapy in which a patients own immune cells are extracted from their tumor, expanded outside the body, and reinfused to fight cancer.
The company markets two products: Amtagvi (lifileucel), an individualized T cell therapy approved for adult patients with previously treated advanced or metastatic melanoma, and Proleukin, an interleukin-2 (IL-2) product used to support TIL therapy and indicated for metastatic melanoma and metastatic renal cell carcinoma.
Iovances broader pipeline extends lifileucel into cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC), alongside next-generation candidates including LN-145 Gen 3, IOV-4001 (gene-edited TIL therapy), IOV-2001 for hematologic cancers, and IOV-3001 to support the TIL regimen. The company maintains research and licensing partnerships with the National Institutes of Health, the National Cancer Institute, Cellectis, Novartis Pharma AG, and Boehringer Ingelheim Biopharmaceuticals.
Originally incorporated in 2007 as Lion Biotechnologies, the company rebranded to Iovance Biotherapeutics in June 2017. Listed on NASDAQ since 2010 within the small-cap health care segment, Iovance operates in the biotechnology sub-industry, a sector characterized by long development cycles, regulatory risk, and reliance on clinical trial outcomes and strategic partnerships for commercialization.
- Amtagvi sales ramp drives quarterly revenue growth
- Lifileucel label expansion into NSCLC and cervical cancer
- Cash burn raises dilution risk as operating losses persist
| Net Income: -353.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.33 > 0.02 and ΔFCF/TA 2.99 > 1.0 |
| NWC/Revenue: 118.0% < 20% (prev 183.4%; Δ -65.33% < -1%) |
| CFO/TA -0.29 > 3% & CFO -270.8m > Net Income -353.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (418.5m) vs 12m ago 29.62% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 30.18% > 50% (prev 22.00%; Δ 8.19% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.36 (Total Current Assets 466.5m - Total Current Liabilities 129.4m) / Total Assets 925.7m |
| B: -3.08 (Retained Earnings -2.85b / Total Assets 925.7m) |
| C: -0.37 (EBIT TTM -354.8m / Avg Total Assets 946.2m) |
| D: 3.54 (Book Value of Equity 721.8m / Total Liabilities 203.9m) |
| Altman-Z'' = -6.47 = D |
| DSRI: 0.86 (Receivables 81.8m/70.9m, Revenue 285.6m/212.7m) |
| GMI: 0.22 (GM 21.72% / 97.45%) |
| AQI: 1.01 (AQ_t 0.31 / AQ_t-1 0.30) |
| SGI: 1.34 (Revenue 285.6m / 212.7m) |
| TATA: -0.09 (NI -353.9m - CFO -270.8m) / TA 925.7m) |
| Beneish M = -3.60 (Cap -4..+1) = AAA |
As of July 08, 2026, the stock is trading at USD 4.35 with a total of 11,573,509 shares traded. Over the past week, the price has changed by +3.33%, over one month by +8.75%, over three months by +31.02% and over the past year by +155.88%.
Current recommended Stop Loss: 3.80 (which is 12.6% or 1.6 ATR below the current price).
Iovance Biotherapeutics has received a consensus analysts rating of 4.08. Therefore, it is recommended to buy IOVA.
- StrongBuy: 5
- Buy: 3
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8.8 | 102.3% |
P/S = 6.2065
P/B = 2.456
Revenue TTM = 285.6m USD
EBIT TTM = -354.8m USD
EBITDA TTM = -321.3m USD
Long Term Debt = 43.9m USD (estimated: total debt 47.8m - short term 3.90m)
Short Term Debt = 3.90m USD (from shortTermDebt, last quarter)
Debt = 47.8m USD (from shortLongTermDebtTotal, last quarter) (leases 46.8m already included)
Net Debt = -265.7m USD (calculated: Debt 47.8m - CCE 313.4m)
Enterprise Value = 1.50b USD (1.77b + Debt 47.8m - CCE 313.4m)
Interest Coverage Ratio = unknown (Ebit TTM -354.8m / Interest Expense TTM 0.0)
EV/FCF = -4.93x (Enterprise Value 1.50b / FCF TTM -305.0m)
FCF Yield = -20.30% (FCF TTM -305.0m / Enterprise Value 1.50b)
FCF Margin = -106.8% (FCF TTM -305.0m / Revenue TTM 285.6m)
Net Margin = -123.9% (Net Income TTM -353.9m / Revenue TTM 285.6m)
Gross Margin = unknown ((Revenue TTM 285.6m - Cost of Revenue TTM 7.29m) / Revenue TTM)
Tobins Q-Ratio = 1.62 (Enterprise Value 1.50b / Total Assets 925.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 47.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -280.3m (EBIT -354.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.60 (Total Current Assets 466.5m / Total Current Liabilities 129.4m)
Debt / Equity = 0.07 (Debt 47.8m / totalStockholderEquity, last quarter 721.8m)
Debt / EBITDA = 0.83 (negative EBITDA) (Net Debt -265.7m / EBITDA -321.3m)
Debt / FCF = 0.87 (negative FCF - burning cash) (Net Debt -265.7m / FCF TTM -305.0m)
Total Stockholder Equity = 705.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.40% (Net Income -353.9m / Total Assets 925.7m)
RoE = -50.17% (Net Income TTM -353.9m / Total Stockholder Equity 705.3m)
RoCE = -47.35% (EBIT -354.8m / Capital Employed (Equity 705.3m + L.T.Debt 43.9m))
RoIC = -35.66% (negative operating profit) (NOPAT -280.3m / Invested Capital 785.9m)
WACC = 12.43% (E(1.77b)/V(1.82b) * Re(12.77%) + D(47.8m)/V(1.82b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 24.43%
[DCF] Fair Price = unknown (Cash Flow -305.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.85 | # QB: -1
Revenue Correlation: 91.97 | Revenue CAGR: 1.52k% | SUE: -0.33 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.13 | Chg30d=+0.00% | Revisions=-17% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=+0.00% | Revisions=-17% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.56 | Chg30d=+0.00% | Revisions=-22% | GrowthEPS=+48.2% | GrowthRev=+37.4%
EPS next Year (2027-12-31): EPS=-0.32 | Chg30d=+0.00% | Revisions=-22% | GrowthEPS=+43.5% | GrowthRev=+37.1%
[Analyst] Revisions Ratio: -29% (up=6, down=12)